首页> Transplantation and cellular therapy> Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies.

Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies.

导出 LinkOut

翻译打印收藏纠错

第一作者： Stephanie J,Lee

第一单位： Fred Hutchinson Cancer Center, Seattle, Washington.

作者： Stephanie J,Lee ^[1] ; Steven,Pavletic ^[2] ; Bruce R,Blazar ^[3] ; Yu,Yao ^[4] ; Ran,Ji ^[5] ; Kathy,Marshall ^[5] ; Corey,Cutler ^[6] ; KD025-208 and ROCKstar Study Investigators

作者单位： Fred Hutchinson Cancer Center, Seattle, Washington. ^[1] Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. ^[2] University of Minnesota, Minneapolis, Minnesota. ^[3] Sanofi, Cambridge, Massachusetts. ^[4] Sanofi, Bridgewater, New Jersey. ^[5] Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: corey_cutler@dfci.harvard.edu. ^[6]

关键词 Belumosudil extended treatment Belumosudil follow-up Belumosudil long-term efficacy Belumosudil long-term safety Chronic GVHD treatment cGVHD long-term outcomes